EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Taysha Gene Therapies's Enterprise Value is $1,613.85 Mil.
Taysha Gene Therapies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-115.33 Mil. Therefore, Taysha Gene Therapies's EV-to-FCF for today is -13.99.
The historical rank and industry rank for Taysha Gene Therapies's EV-to-FCF or its related term are showing as below:
TSHA'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.51 Med: -5.3 Max: -0.09
Current: -13.99
During the past 7 years, the highest EV-to-FCF of Taysha Gene Therapies was -0.09. The lowest was -21.51. And the median was -5.30.
TSHA's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs TSHA: -13.99
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taysha Gene Therapies's PE Ratio (TTM) for today is calculated as:
Taysha Gene Therapies's share price for today is $6.34.
Taysha Gene Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's EV-to-FCF falls into.
Taysha Gene Therapies's current Enterprise Value is $1,613.85 Mil.
Taysha Gene Therapies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-115.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a EV-to-FCF of -13.99 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taysha Gene Therapies and its competitors. According to the industry distribution chart, Taysha Gene Therapies ranks #999999 out of 330 companies in the Biotechnology industry.
Is Taysha Gene Therapies' EV-to-FCF too high?
Taysha Gene Therapies' current EV-to-FCF is -13.99. Based on the distribution chart, Taysha Gene Therapies ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' EV-to-FCF compare to ANAB and ABSI?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #999999 out of 330 companies for EV-to-FCF. This places Taysha Gene Therapies in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current EV-to-FCF is -13.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $6.34 — trading 818.8% above its estimated fair value. The current EV-to-FCF is -13.99. Taysha Gene Therapies' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current EV-to-FCF is -13.99 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $6.34 is trading 818.8% above its estimated GF Value™ of $0.69.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
EV-to-FCF: -13.99
GF Value™: $0.69 vs. price of $6.34 (818.8% above fair value)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
27GF Score
Get the complete analysis for TSHA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
